达诺瑞韦联合长效α-干扰素治疗基因3型慢性丙型肝炎患者疗效研究

Short-term efficacy of danorevir and peginterferon-αin the treatment of patients with genotype 3 infected chronic hepatitis C

目的研究在达诺瑞韦基础上联合长效α-干扰素治疗基因3型慢性丙型肝炎(CHC)患者的临床疗效。方法2017年10月~2019年5月我院收治的132例基因3型CHC患者,其中66例(对照组)接受聚乙二醇干扰素α-2a联合利巴韦林治疗24周,另66例(观察组)接受聚乙二醇干扰素α-2a和利巴韦林治疗的基础上,加用利托那韦和达诺瑞韦联合治疗12周。所有患者随访24周。结果在治疗2 w、4 w和12 w末,观察组病毒学应答率分别为90.9%、97.0%和100.0%,显著高于对照组的66.7%、75.8%和81.8%(P<0.05);在治疗结束后24 w随访时,观察组持续病毒学应答率(SVR)为92.4%,显著高于对照组的74.2%(P<0.05);在治疗12 w末,两组外周血白细胞计数、血小板计数和血红蛋白水平变化无统计学差异(P>0.05),两组不良反应发生率比较差异也无统计学意义(P>0.05)。结论应用利托那韦和达诺瑞韦联合标准治疗方案治疗基因3型CHC患者临床疗效确切,安全性较好,值得进一步观察。

Objective The aim of this study was to investigate the short-term efficacy of danorevir and peginterferon-αin the treatment of patients with genotype 3 infected chronic hepatitis C(CHC).Methods 132 patients with genotype 3 infected CHC were admitted to our hospital between October 2017 and May 2019,and 66 patients were treated with peginterferon-2a and ribavirin for 24 weeks,and another 66 patients were treated with ritonavir and danorevir at base of standardized therapy for 12 weeks.All patients were followed-up for 24 weeks.Results At the end of 2 week,4 week and 12 week treatment,the virological response rates in the combination group were 90.9%,97.0%and 100.0%,respectively,significantly higher than 66.7%,75.8%and 81.8%in standardized therapy-treated group(P<0.05);at the end of 24 week of follow-up after treatment,the sustained virological response(SVR)in the combination group was 92.4%,significantly higher than 74.2%in the control group(P<0.05);there were no statistically significant differences in white blood cell counts,platelet counts and hemoglobin levels in the two groups(P>0.05)and there wereno significant differences in the incidences of adverse reactions between the two groups(P>0.05).Conclusion The application of ritonavir and danorevir at base of standardized therapy in the treatment of patients with CHC and genotype 3 infection is efficacious and safe,which warrants further investigation.